Document Detail


A blueprint for engineering cell fate: current technologies to reprogram cell identity.
MedLine Citation:
PMID:  23277278     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Human diseases such as heart failure, diabetes, neurodegenerative disorders, and many others result from the deficiency or dysfunction of critical cell types. Strategies for therapeutic tissue repair or regeneration require the in vitro manufacture of clinically relevant quantities of defined cell types. In addition to transplantation therapy, the generation of otherwise inaccessible cells also permits disease modeling, toxicology testing and drug discovery in vitro. In this review, we discuss current strategies to manipulate the identity of abundant and accessible cells by differentiation from an induced pluripotent state or direct conversion between differentiated states. We contrast these approaches with recent advances employing partial reprogramming to facilitate lineage switching, and discuss the mechanisms underlying the engineering of cell fate. Finally, we address the current limitations of the field and how the resulting cell types can be assessed to ensure the production of medically relevant populations.
Authors:
Samantha A Morris; George Q Daley
Related Documents :
23617728 - Papillary carcinoma of the thyroid: high expression of cox-2 and low expression of kai-...
25014538 - The toxic effect of air on primary human retinal pigment epithelium cells.
24951878 - Cycp2;1 integrates genetic and nutritional information to promote meristem cell divisio...
24457968 - Oct4 as a target of mir-34a stimulates p63 but inhibits p53 to promote human cell trans...
20186548 - Hl-1 cells express an inwardly rectifying k+ current activated via muscarinic receptors...
520758 - In vitro cultivation of human testicular embryonal carcinoma and establishment of a new...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review     Date:  2013-01-01
Journal Detail:
Title:  Cell research     Volume:  23     ISSN:  1748-7838     ISO Abbreviation:  Cell Res.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-03     Completed Date:  2013-06-18     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  9425763     Medline TA:  Cell Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  33-48     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cell Differentiation
Cell Engineering*
Hepatocytes / cytology,  metabolism
Humans
Induced Pluripotent Stem Cells / cytology*,  metabolism
Myocytes, Cardiac / cytology,  metabolism
Neurons / cytology,  metabolism
Nuclear Reprogramming
Transcription Factors / metabolism
Grant Support
ID/Acronym/Agency:
R24 DK092760/DK/NIDDK NIH HHS; R24DK092760/DK/NIDDK NIH HHS; RC4-DK090913/DK/NIDDK NIH HHS; U01 HL100001/HL/NHLBI NIH HHS; UO1-HL100001/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Transcription Factors
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Proteomics in HepG2 hepatocarcinoma cells with stably silenced expression of PRDX1.
Next Document:  XBP-1u suppresses autophagy by promoting the degradation of FoxO1 in cancer cells.